Abstract
The anti-infectives market is forecast to expand at a CAGR of 4.8%over the period 2005-11, driven largely by gains in the anti-bacterial and anti-viral classes. This represents significant market opportunity for pharma companies to expand their sales potential by targeting high growth markets. ‘The Global Anti-Infectives Market Outlook to 2011’ provides comprehensive coverage of the anti-infectives market, incorporating a detailed epidemiological analysis of the major indications and the key factors impacting their prevalence. Analysis of the major brands and profiles of the leading pharmaceutical companies will ensure that you can plan effectively, evaluate key changes in the competitive landscape, and identify potential growth areas within the global anti-infectives market. Use this report to assess anti-infective therapies that will be crucial to maintaining positive sales growth, analyze the marketed product portfolio and R&D pipelines of the leading 10 pharmaceutical companies in the global anti-infectives market.
Table of Contents
Executive Summary
- Patient potential
- Global market analysis
- Pipeline analysis
- Competitive landscape
Chapter 1 Epidemiology of Anti-infectives market
- Summary
- Introduction
- Bacterial infections
- Overview
- Respiratory tract infections
- Urinary tract infections
- Skin and skin structure infections
- Diagnosis, treatment and management
- Respiratory tract infections
- Urinary tract infections
- Skin and skin structure infections
- Epidemiology
- Respiratory tract infections
- Urinary tract infections
- Skin and skin structure infections
- Forecast epidemiology
- Respiratory tract infections
- Urinary tract infections
- Skin and skin structure infections
- Viral infections
- Hepatitis
- Overview
- Diagnosis, treatment and management
- Epidemiology
- Forecast epidemiology
- Influenza
- Overview
- Diagnosis, treatment and management
- Epidemiology
- Forecast epidemiology
- Herpes
- Overview
- Diagnosis, treatment and management
- Epidemiology
- Forecast epidemiology
- Vaccines
- Tetanus, diphtheria, pertussis
- Overview
- Diagnosis, treatment and management
- Epidemiology
- Mumps, measles and rubella
- Overview
- Diagnosis, treatment and management
- Epidemiology
- Polio
- Overview
- Diagnosis, treatment and management
- Epidemiology
- Fungal infections
- Overview
- Diagnosis, treatment and management
- Epidemiology
- Forecast epidemiology
Chapter 2 Global market analysis
- Summary
- Introduction
- Market analysis by country
- Licensing trends
- Market analysis by drug class
- Leading brands dynamics
- Key events in the anti-infectives market
- Safety warning issued for Sanofi-Aventis' Ketek (telithromycin)
- Serious adverse effects reported with the use of penicillins
- Launch of new innovative class of drugs
- Wyeth' s Prevnar gains from being the first vaccine to reach blockbuster status in 2005
- Increased competition within the hepatitis B market
- Arrival of generic competition to market leading products in the antiinfectives' market
- Anti-virals
- Leading brands of anti-viral treatments
- Key brands analysis
- Anti-Virals sales forecasts to 2011
- Vaccines
- Key brands analysis
- Vaccines sales forecasts to 2011
- Anti-bacterials
- Market analysis by drug class
- Leading brands of anti-bacterial treatments
- Macrolides
- Key brands analysis
- Beta-lactams
- Key brands analysis
- Other anti-biotics
- Key brand analysis
- Penicillins
- Market dynamics
- Key brands analysis
- Cephalosporins market analysis
- Market dynamics
- Key brands analysis
- Tetracyclines market analysis
- Market dynamics
- Key brands analysis
- Fluroquinolones
- Market dynamics
- Key brands analysis
- Anti-bacterials sales forecasts to 2011
- Anti-fungals
- Market analysis by drug class
- Leading brands of the anti-fungal market
- Market dynamics
- Key brands analysis
- Anti-fungals sales forecasts to 2011
- Total anti-infective market sales forecasts to 2011
Chapter 3 Pipeline analysis
- Summary
- Introduction
- Key trends in R&D
- The therapeutic area pipeline
- Leading drugs in development
- Profiles of key pipeline products
- Phase III compounds
- Albuferon (albinterferon alpha 2b)
- Maribavir
- Ceftobiprole
- Drugs in registration
- Arbelic (telavancin)
- Zeven (dalbavancin)
- Mycograb (efungumab)
- Recently marketed drugs
- Tygacil (tigecycline)
- Doripenem
- Baraclude (entecavir)
- Tyzeka/Sebivo (telbivudine)
- Noxafil (posaconazole)
- Eraxis (anidulafungin)
- Pipeline forecasts
- Factors affecting forecasts
- Anti-infectives pipeline forecasts
Chapter 4 Competitive landscape
- Summary
- Introduction
- Company market shares
- GlaxoSmithKline
- Overview
- Sales focus by drug class
- Marketed product portfolio
- R&D pipeline analysis
- Strategic and growth analysis
- Drivers of growth
- Resistors of growth
- Pfizer
- Overview
- Sales focus by drug class
- Marketed product portfolio
- R&D pipeline analysis
- Strategic and growth analysis
- Drivers of growth
- Resistors of growth
- Novartis
- Overview
- Sales focus by drug class
- Marketed product portfolio
- R&D pipeline analysis
- Strategic and growth analysis
- Drivers of growth
- Resistors of growth
- Sanofi-Aventis
- Overview
- Sales focus by drug class
- Marketed product portfolio
- R&D pipeline analysis
- Strategic and growth analysis
- Drivers of growth
- Resistors of growth
- Merck
- Overview
- Sales focus by drug class
- Marketed product portfolio
- R&D pipeline analysis
- Strategic and growth analysis
- Drivers of growth
- Resistors of growth
- Johnson & Johnson
- Overview
- Sales focus by drug class
- Marketed product portfolio
- R&D pipeline analysis
- Strategic and growth analysis
- Drivers of growth
- Resistors of growth
- Roche
- Overview
- Sales focus by drug class
- Marketed product portfolio
- R&D pipeline analysis
- Strategic and growth analysis
- Drivers of growth
- Resistors of growth
- Wyeth
- Overview
- Sales focus by drug class
- Marketed product portfolio
- R&D pipeline analysis
- Strategic and growth analysis
- Drivers of growth
- Resistors of growth
- Abbott
- Overview
- Sales focus by drug class
- Marketed product portfolio
- R&D pipeline analysis
- Strategic and growth analysis
- Drivers of growth
- Resistors of growth
- Schering-Plough
- Overview
- Sales focus by drug class
- Marketed product portfolio
- R&D pipeline analysis
- Strategic and growth analysis
- Drivers of growth
- Resistors of growth
Chapter 5 Appendix
- IMS data
- J1 Systemic antibiotics
- J2 systemic agents for fungal infections
- J3 systemic sulphonamides
- J5 Antivirals for systemic use
- J7 Vaccines
- Index
List of Figures
- Figure 2.1: Global anti-infectives market share by geography, 2005
- Figure 2.2: Sales of types of anti-infectives brands, 2004-5
- Figure 2.3: Competitive dynamics of the drug classes in the global anti-infectives market, 2004-
- Figure 2.4: Competitive dynamics of the drug classes in the global anti-infectives market, 2004-
- Figure 2.5: Competitive dynamics of the leading anti-viral treatments in the global anti-infectives market, 2004-5
- Figure 2.6: Competitive dynamics of the leading vaccines in the global anti-infectives market, 2004-5
- Figure 2.7: Competitive dynamics of the global anti-bacterial market by drug class, 2005
- Figure 2.8: Competitive dynamics of the ten leading brands in the anti-bacterial drug class, 2005
- Figure 2.9: Competitive dynamics of the ten leading brands in the anti-fungal drug class, 2005
- Figure 3.10: Prevailing R&D approaches, 2006
- Figure 3.11: The anti-infectives pipeline by indication and stage of development, 2006
- Figure 3.12: Leading recently launched products and late-stage R&D in the anti-infectives market, 2005
- Figure 4.13: Competitive dynamics of the leading players in the global anti-infectives market, 2005
- Figure 4.14: GSK' s anti-infectives sales, 2005
- Figure 4.15: Pfizer' s anti-infectives sales, 2005
- Figure 4.16: Novartis' anti-infectives sales, 2005
- Figure 4.17: Sanofi-Aventis' anti-infectives sales, 2005
- Figure 4.18: Merck' s anti-infectives sales, 2005
- Figure 4.19: Johnson & Johnson anti-infectives sales, 2005
- Figure 4.20: Roche' s anti-infectives sales, 2005
- Figure 4.21: Wyeth' s anti-infectives sales, 2005
- Figure 4.22: Abbott' s anti-infectives sales, 2005
- Figure 4.23: Schering-Plough' s anti-infectives sales, 2005
List of Tables
- Table 1.1: Estimated prevalence of infective diseases across seven major pharmaceutical markets, 2005
- Table 1.2: Estimated incidence of community acquired pneumonia infections across seven major markets, 2005
- Table 1.3: Estimated incidence of uRTIs caused by streptococcus infection across seven major markets, 2005
- Table 1.4: Estimated incidence of community acquired urinary tract infections across seven major markets, 2005
- Table 1.5: Estimated incidence of bacterial skin and skin structure infections across seven major markets, 2005
- Table 1.6: Forecast epidemiology of CAP across the seven major markets, 2005-11
- Table 1.7: Forecast epidemiology of uRTIs caused by streptococcus infection across the seven major markets, 2005-11
- Table 1.8: Forecast epidemiology of urinary tract infections across the seven major markets, 2005-11
- Table 1.9: Forecast epidemiology of skin and skin structure infections across the seven major markets, 2005-11
- Table 1.10: Estimated prevalence of HBV and HCV across the seven major markets, 2005
- Table 1.11: Forecast epidemiology of HBV and HCV across the seven major markets, 2005-11
- Table 1.12: Estimated prevalence of influenza across the seven major markets, 2005
- Table 1.13: Estimated seroprevalence of HSV-1 and HSV-2 across the seven major markets, 2005
- Table 1.14: Forecast seroprevalence of HSV-1 and HSV-2 across the seven major markets, 2005-11
- Table 1.15: Estimated vaccine coverage and incidence of DPT across the seven major markets, 2005
- Table 1.16: Estimated vaccine coverage and incidence of MMR across the seven major markets, 2005
- Table 1.17: Estimated vaccine coverage and incidence of polio across the seven major markets, 2005
- Table 1.18: Estimated incidence of systemic fungal infections in across seven major markets, 2005
- Table 1.19: Forecast epidemiology of systemic fungal infections across the seven major markets, 2005-11
- Table 2.20: Breakdown of the global Anti-infective market by drug class, 2001-05
- Table 2.21: Leading brands in the global Anti-infectives market, 2004-05
- Table 2.22: Breakdown of the global anti-viral market by drug class, 2001-05
- Table 2.23: Leading anti-virals in the global anti-infectives market,
- Table 2.24: Anti-virals sales forecast, 2005-11
- Table 2.25: Leading vaccines in the global anti-infectives market,
- Table 2.26: Vaccines sales forecast, 2005-11
- Table 2.27: Breakdown of the global anti-bacterial market by drug class, 2001-05
- Table 2.28: Leading Anti-bacterials in the global anti-infectives market,
- Table 2.29: Leading macrolides in the global anti-infectives market,
- Table 2.30: Overview of Pfizer' s Zithromax franchise
- Table 2.31: Leading ' other' beta-lactams in the global anti-infectives market,
- Table 2.32: Leading ' other' anti-biotics in the global anti-infectives market,
- Table 2.33: Leading penicillins in the global anti-infectives market,
- Table 2.34: Leading cephalosporin brands in the global anti-bacterials market, 2004-05
- Table 2.35: Leading tetracycline brands in the global anti-bacterials market, 2004-05
- Table 2.36: Leading fluoroquinolones brands in the global anti-infectives market, 2004-5
- Table 2.37: Anti-bacterials' sales forecast, 2005-11
- Table 2.38: Anti-bacterials' sales forecast, 2005-11
- Table 2.39: Anti-bacterials' sales forecast, 2005-11
- Table 2.40: The global anti-fungal market by drug class, 2001-05
- Table 2.41: Leading anti-fungals brands in the global anti-infectives market, 2004-5
- Table 2.42: Anti-fungal sales forecast, 2005-11
- Table 2.43: Therapeutic sales forecasts by drug class, 2005-11
- Table 3.44: Anti-infectives pipeline forecasts, 2006-11
- Table 4.45: Leading players in the global anti-infectives market, 2004-5
- Table 4.46: GSK' s anti-infectives product portfolio, 2004-5
- Table 4.47: GSK' s anti-infectives R&D product pipeline, 2006
- Table 4.48: Pfizer' s anti-infectives product portfolio, 2004-5
- Table 4.49: Pfizer' s anti-infectives R&D product pipeline, 2006
- Table 4.50: Novartis' anti-infectives product portfolio, 2004-5
- Table 4.51: Novartis' anti-infectives R&D product pipeline, 2006
- Table 4.52: Sanofi-Aventis' anti-infectives product portfolio, 2004-5
- Table 4.53: Sanofi-Aventis anti-infectives R&D product pipeline, 2006
- Table 4.54: Merck' s anti-infectives product portfolio, 2004-5
- Table 4.55: Merck' s anti-infectives R&D product pipeline, 2006
- Table 4.56: Johnson & Johnson anti-infectives product portfolio, 2004-5
- Table 4.57: Johnson & Johnson' s anti-infectives R&D product pipeline, 2006
- Table 4.58: Roche' s anti-infectives product portfolio, 2004-5
- Table 4.59: Roche' s anti-infectives R&D product pipeline, 2006
- Table 4.60: Wyeth' s anti-infectives product portfolio, 2004-5
- Table 4.61: Wyeth' s anti-infectives R&D product pipeline, 2006
- Table 4.62: Abbott' s anti-infectives product portfolio, 2004-5
- Table 4.63: Abbott' s anti-infectives R&D product pipeline, 2006
- Table 4.64: Schering-Plough' s anti-infectives product portfolio, 2004-5
- Table 4.65: Schering-Plough' s anti-infectives R&D product pipeline, 2006
